EGFR and non-small cell lung carcinoma: The EGFR T790M mutation is the primary cause of drug resistance in 50–60% of instances, while activating genomic alterations in other kinases, such as ALK, ROS1, MET, RET, NTRK, and BRAF, have been validated as targets in NSCLC therapy (Figure 1) (16).